Restricted accessResearch articleFirst published online 2024-6
Who Provides Outpatient Clinical Care for Adults With ADHD? Analysis of Healthcare Claims by Types of Providers Among Private Insurance and Medicaid Enrollees,2021
To characterize provider types delivering outpatient care overall and through telehealth to U.S. adults with ADHD.
Method:
Using employer-sponsored insurance (ESI) and Medicaid claims, we identified enrollees aged 18 to 64 years who received outpatient care for ADHD in 2021. Billing provider codes were used to tabulate the percentage of enrollees receiving ADHD care from 10 provider types overall and through telehealth.
Results:
Family practice physicians, psychiatrists, and nurse practitioners/psychiatric nurses were the most common providers for adults with ESI, although the distribution of provider types varied across states. Lower percentages of adults with Medicaid received ADHD care from physicians. Approximately half of adults receiving outpatient ADHD care received ADHD care by telehealth.
Conclusion:
Results may inform the development of clinical guidelines for adult ADHD and identify audiences for guideline dissemination and education planning.
AdamisD.FlynnC.WrigleyM.GavinB.McNicholasF. (2022). ADHD in adults: A systematic review and meta-analysis of prevalence studies in outpatient psychiatric clinics. Journal of Attention Disorders, 26(12), 1523–1534. https://doi.org/10.1177/10870547221085503
2.
AdlerL. A.FarahbakhshianS.RomeroB.FloodE.DollH. (2019). Healthcare provider perspectives on diagnosing and treating adults with attention-deficit/hyperactivity disorder. Postgraduate Medicine, 131(7), 461–472. https://doi.org/10.1080/00325481.2019.1647080
3.
American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.).
4.
AndrillaC. H. A.PattersonD. G.GarbersonL. A.CoulthardC.LarsonE. H. (2018). Geographic variation in the supply of selected behavioral health providers. American Journal of Preventive Medicine, 54(6S3), S199–S207. https://doi.org/10.1016/j.amepre.2018.01.004
5.
BarbaresiW. J.CampbellL.DiekrogerE. A.FroehlichT. E.LiuY. H.O’MalleyE.PelhamW. E. J.PowerT. J.ZinnerS. H.ChanE. (2020). Society for Developmental and Behavioral Pediatrics clinical practice guideline for the assessment and treatment of children and adolescents with complex attention-deficit/hyperactivity disorder. Journal of Developmental & Behavioral Pediatrics, 41, S35–S57. https://doi.org/10.1097/DBP.0000000000000770
6.
BishopT. F.PressM. J.KeyhaniS.PincusH. A. (2014). Acceptance of insurance by psychiatrists and the implications for access to mental health care. JAMA Psychiatry, 71(2), 181. https://doi.org/10.1001/jamapsychiatry.2013.2862
7.
BoardA. R.GuyG.JonesC. M.HootsB. (2020). Trends in stimulant dispensing by age, sex, state of residence, and prescriber specialty — United States, 2014–2019. Drug and Alcohol Dependence, 217, 108297. https://doi.org/10.1016/j.drugalcdep.2020.108297
8.
BreauxR.DunnN. C.CashA. R.ShroffD. M. (2023). Telemedicine to manage ADHD. In MatsonJ. L. (Ed.), Clinical handbook of ADHD assessment and treatment across the lifespan (pp. 591-609). Springer International Publishing. https://doi.org/10.1007/978-3-031-41709-2_23
9.
ButtD. A.StephensonE.KaliaS.MoineddinR.TuK. (2023). Patient visits and prescriptions for attention-deficit/hyperactivity disorder from 2017-2021: Impacts of COVID-19 pandemic in primary care. PLoS One, 18(3), e0281307. https://doi.org/10.1371/journal.pone.0281307
10.
CallenE. F.ClayT. L.AlaiJ.GoodmanD. W.AdlerL. A.ShieldsJ.FaraoneS. V. (2023). Progress and pitfalls in the provision of quality care for adults with attention deficit hyperactivity disorder in primary care. Journal of Attention Disorders, 27(6), 575–582. https://doi.org/10.1177/10870547231155875
11.
ChildressA.SibleyM.SolantoM. V.WiznitzerM.NewcornJ. H. (2023). Guidelines in the united states for the diagnosis and treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Why they are needed. Psychiatric Annals, 53(10), 461–469. https://doi.org/10.3928/00485713-20230911-04
12.
DanielsonM. L.BohmM. K.NewsomeK.ClaussenA. H.KaminskiJ. W.GrosseS. G.SiwakotiL.ArifkhanovaA.BitskoR. H.RobinsonL. R. (2023). Trends in prescription stimulant fills among commercially insured children and adults — United States, 2016–2021. MMWR Morbidity and Mortality Weekly Report, 72(13), 327–332. https://doi.org/10.15585/mmwr.mm7213a1
13.
DoD.LeeT.BablyM.InnehI. A.PatelU. (2023). Prevalence and predictors of multimodal treatment among U.S. adults newly diagnosed with ADHD. American Journal of Preventive Medicine. Advance online publication. https://doi.org/10.1016/j.amepre.2023.11.018
14.
FaraoneS. V.BanaschewskiT.CoghillD.ZhengY.BiedermanJ.BellgroveM. A.NewcornJ. H.GignacM.Al SaudN. M.ManorI.RohdeL. A.YangL.CorteseS.AlmagorD.SteinM. A.AlbattiT. H.AljoudiH. F.AlqahtaniM. M. J.AshersonP.. . . WangY. (2021). The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience & Biobehavioral Reviews, 23(7), 519–529. https://doi.org/10.1016/j.neubiorev.2021.01.022
15.
GoodmanD. W.MattinglyG. (2023). Practice guidelines development: The APSARD United States guidelines for the diagnosis and treatment of ADHD in adults. Psychiatric Annals, 53(10), 449–454. https://doi.org/10.3928/00485713-20230911-05
16.
GoodmanD. W.SurmanC. B.SchererP. B.SalinasG. D.BrownJ. J. (2012). Assessment of physician practices in adult attention-deficit/hyperactivity disorder. Primary Care Companion to the Journal of Clinical Psychiatry, 14(4). https://doi.org/10.4088/PCC.11m01312
17.
HartL. C.GrosseS. D.DanielsonM. L.BaumR. A.KemperA. R. (2021). Changes in provider type and prescription refills among privately insured children and youth with ADHD. Journal of Attention Disorders, 25(14), 2028–2036. https://doi.org/10.1177/108705472095
18.
HinshawS. P.NguyenP. T.O’GradyS. M.RosenthalE. A. (2022). Annual research review: Attention-deficit/hyperactivity disorder in girls and women: Underrepresentation, longitudinal processes, and key directions. Journal of Child Psychology and Psychiatry, 63(4), 484–496. https://doi.org/10.1111/jcpp.13480
19.
HollingdaleJ.AdamoN.TierneyK. (2021). Impact of COVID-19 for people living and working with ADHD: A brief review of the literature. AIMS Public Health, 8(4), 581–597. https://doi.org/10.3934/publichealth.2021047
20.
HuangH.HuangH.SpottswoodM.GhaemiN. (2020). Approach to evaluating and managing adult attention-deficit/hyperactivity disorder in primary care. Harvard Review of Psychiatry, 28(2), 100–106. https://doi.org/10.1097/hrp.0000000000000248
21.
KesslerR.C.AdlerL.BarkleyR.BiedermanJ.ConnersK. C.DemlerO.FaraoneS. V.GreenhillL. L.HowesM. J.SecnikK.SpencerT.UstunT. B.WaltersE. E.ZaslavskyA. M. (2006). The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. American Journal of Psychiatry, 163(4), 716–723. https://doi.org/10.1176/ajp.2006.163.4.716
22.
LeebR. T.DanielsonM. L.BitskoR. H.CreeR. A.Godfred-CatoS.HughesM. M.PowellP.FirchowB.HartL. C.Lebrun-HarrisL. A. (2020). Support for transition from adolescent to adult health care among adolescents with and without mental, behavioral, and developmental disorders - United States, 2016-2017. MMWR Morbidity and Mortality Weekly Report, 69(34), 1156–1160. https://doi.org/10.15585/mmwr.mm6934a2
23.
Modesto-LoweV.BoninsegnaK.FredeenM. (2023). Improving attention-deficit/hyperactivity disorder recognition in family practice. Family Practice. Advance online publication. https://doi.org/10.1093/fampra/cmad026
24.
SibleyM. H.FaraoneS. V.NiggJ. T.SurmanC. B. H. (2023). Sudden increases in U.S. stimulant prescribing: Alarming or not?Journal of Attention Disorders, 27(6), 571–574. https://doi.org/10.1177/10870547231164155
25.
SimonV.CzoborP.BálintS.MészárosA.BitterI. (2009). Prevalence and correlates of adult attention-deficit hyperactivity disorder: Meta-analysis. British Journal of Psychiatry, 194(3), 204–211. https://doi.org/10.1192/bjp.bp.107.048827
26.
SongP.ZhaM.YangQ.ZhangY.LiX.RudanI. (2021). The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis. Journal of Global Health, 11, 04009. https://doi.org/10.7189/jogh.11.04009
WaiteR.VlamR. C.Irrera-NewcombM.BabcockT. (2013). The diagnosis less traveled: NPs’ role in recognizing adult ADHD. Journal of the American Association of Nurse Practitioners, 25(6), 302–308. https://doi.org/10.1111/j.1745-7599.2012.00788.x
29.
WillcuttE. (2012). The prevalence of DSM-IV Attention-Deficit/Hyperactivity Disorder: A meta-analytic review. Neurotherapeutics, 9(3), 490–499. https://doi.org/10.1007/s13311-012-0135-8
30.
WolraichM. L.HaganJ. F.AllanC.ChanE.DavisonD.EarlsM.EvansS. W.FlinnS. K.FroehlichT.FrostJ.HolbrookJ. R.LehmannC. U.LessinH. R.OkechukwuK.PierceK. L.WinnerJ. D.ZurhellenW., & Subcommittee on Children and Adolescents with Attention-Deficit/Hyperactive Disorder. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics144(4), e20192528. https://doi.org/10.1542/peds.2019-2528
31.
YeungA.NgE.Abi-JaoudeE. (2022). TikTok and attention-deficit/hyperactivity disorder: A cross-sectional study of social media content quality. Canadian Journal of Psychiatry, 67(12), 899–906. https://doi.org/10.1177/07067437221082854
32.
ZanganiC.OstinelliE. G.SmithK. A.HongJ. S. W.MacdonaldO.ReenG.ReidK.VincentC.Syed SheriffR.HarrisonP. J.HawtonK.PitmanA.BaleR.FazelS.GeddesJ. R.CiprianiA. (2022). Impact of the COVID-19 pandemic on the global delivery of mental health services and telemental health: Systematic review. JMIR Mental Health, 9(8), e38600. https://doi.org/10.2196/38600
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
